FASLG and cancer: MMPs and ADAMs are responsible for the generation of soluble CD95L, that might promote metastatic occurrence in cancers or stimulate trafficking/activation of immune cells in chronic inflammatory disorders and thus, inhibiting MMP or ADAM activity could represent an attractive therapeutic strategy in these pathologies (Figure 3).